STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3606 by analyst upside · 2026-08-12
JNJ
Johnson & Johnson
Healthcare · Market Cap $626B · P/E 30.2x
ANALYST PRICE TARGET
+4.9%
implied upside to consensus target
Current Price $259.8
Consensus Target $272.5
Bull Target $305.0
Bear Target $190.0
Analysts Covering 22
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
11
Hold
6
Sell
0
52-Week Low $171.81
52-Week High $274.9
YTD Return +26.7%
FUNDAMENTALS
Market Cap $626B
P/E Ratio (TTM) 30.2x
Forward P/E 21.1x
EPS (TTM) $8.61
PEG Ratio 4.32
Dividend Yield 2.05%
Revenue (TTM) $97.9B
Profit Margin 21.5%
52-WEEK RANGE
52-Week Low $171.81
52-Week High $274.9
Current Price $259.8
Bear Target $190.0
Bull Target $305.0
● Now $259.8 ● Target $272.5
TRADING DATA
Avg Volume 8.3M
YTD Return +26.7%
Analyst Count 22
Consensus Buy
Upside to Target +4.9%
Last Updated 2026-08-12

ANALYST SUMMARY

Johnson & Johnson (JNJ) is currently trading at $259.8 with a Wall Street consensus price target of $272.5, implying potential upside of 4.9% over the next 12 months. 22 analysts currently cover JNJ, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $305.0, while the most cautious has a target of $190.0.

JNJ operates in the Healthcare sector with a market capitalisation of $626B. The stock is up 26.7% year-to-date and is currently trading near the upper end of its 52-week range of $171.81 – $274.9.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for JNJ, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners ↑ Upgrade
Market Perform → Outperform 2026-05-13 29% win rate (7 calls)
Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-04-15 Building track record
Stifel - Reiterated
Hold → Hold 2026-04-15 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-04-15 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-04-10 Building track record
RBC Capital reit
Outperform → Outperform 2026-03-30 Building track record
Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-03-19 Building track record
HSBC - Reiterated
Buy → Buy 2026-03-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
24/30
Consensus clarity
21/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →